Clinical Trial Detail

NCT ID NCT02898207
Title Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube serous adenocarcinoma

Advanced Solid Tumor

ovarian serous carcinoma

triple-receptor negative breast cancer

peritoneal serous adenocarcinoma

Therapies

Olaparib + Onalespib

Age Groups: adult senior

No variant requirements are available.